[Phenotypic Change in a Gastric GIST after NAC‒Imatinib-A Case Report]

Junki Yamada1, Kei Sato, Selen Tomita

  • 1Dept. of Surgery, Yokohama City Minato Red Cross Hospital.

Insights

This case study highlights diagnostic challenges in gastrointestinal stromal tumors (GIST) after neoadjuvant chemotherapy (NAC). Post-NAC histopathology significantly altered findings, impacting accurate diagnosis.

Area of Science:

  • Gastroenterology
  • Surgical Oncology
  • Pathology

Background:

  • Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract.
  • Neoadjuvant chemotherapy (NAC) is increasingly used for GIST management, but its impact on histopathological features is not fully understood.
  • Accurate diagnosis of GIST relies on characteristic histopathological findings and immunohistochemical (IHC) staining.

Purpose of the Study:

  • To report a challenging case of GIST diagnosis following NAC.
  • To review the literature on IHC changes in GIST after NAC.
  • To emphasize the importance of considering post-treatment alterations in histopathology.

Main Methods:

  • Case presentation of a 53-year-old male with epigastric pain and a submucosal tumor.
  • Initial diagnosis of GIST based on gastroscopy, biopsy, and IHC (c-kit positive).
  • Surgical resection after NAC, followed by detailed histopathological analysis of the resected specimen.

Main Results:

  • Initial biopsy diagnosed GIST with spindle cell proliferation and c-kit positivity.
  • Post-NAC histopathological findings of the resected specimen differed significantly from the biopsy.
  • Complete resection was achieved, but postoperative diagnosis was complicated by altered histology.

Conclusions:

  • Neoadjuvant chemotherapy can markedly alter GIST histopathology, posing diagnostic challenges.
  • There is a paucity of literature on IHC changes in GIST following NAC.
  • This case underscores the need for careful interpretation of post-NAC specimens and further research into treatment-induced histological modifications.

Related Concept Videos

Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.4K
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
2.7K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
691
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.3K
Gastric Motility01:16

Gastric Motility

Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
3.6K